Investment Rating - The investment rating for the company is "Buy" with a current price of 243.11 CNY and a fair value of 333.42 CNY [3][19]. Core Insights - The company reported a revenue of 5.929 billion CNY for 2025, representing a year-on-year growth of 15.78%. The net profit attributable to shareholders was 1.836 billion CNY, up 11.63% year-on-year [11]. - The WPS 365 business achieved significant growth, with revenue increasing by 64.93% to 720 million CNY. This business integrates document, collaboration, and AI capabilities, providing a comprehensive AI office solution [12][13]. - The company anticipates continued rapid growth in revenue and profit, with projected revenues of 7.092 billion CNY, 8.525 billion CNY, and 10.028 billion CNY for 2026, 2027, and 2028, respectively [14]. Financial Performance - The company achieved an EBITDA of 1.512 billion CNY in 2024, with a projected increase to 3.104 billion CNY by 2028 [2]. - The earnings per share (EPS) are expected to grow from 3.56 CNY in 2024 to 6.70 CNY in 2028, reflecting a strong upward trend in profitability [2]. - The return on equity (ROE) is projected to improve from 14.5% in 2024 to 16.8% in 2028, indicating enhanced efficiency in generating profits from equity [2]. Business Segments - The WPS personal business generated revenue of 3.626 billion CNY, growing by 10.42% year-on-year, while the software business achieved revenue of approximately 1.461 billion CNY, up 15.24% [12][13]. - The WPS AI application has seen rapid user growth, with domestic monthly active users exceeding 80.13 million, a 307% increase year-on-year [13]. Valuation - The fair value of the company is estimated at approximately 154.5 billion CNY, translating to a per-share value of 333.42 CNY based on the latest total share count [15][19]. - The valuation approach includes a price-to-sales (P/S) ratio for subscription services and a price-to-earnings (P/E) ratio for the WPS software business, reflecting the distinct characteristics of each segment [15].

Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 53.05 and a fair value of HKD 76.49 [9]. Core Insights - The company's Q4 revenue exceeded expectations, reaching RMB 39.6 billion, with a year-over-year growth of 12% and a quarter-over-quarter growth of 11% [9]. - The company is firmly advancing its AI strategy, which is expected to enhance its commercial capabilities [9]. - The report anticipates total revenue for 2026 and 2027 to reach RMB 1,484 billion and RMB 1,579 billion, representing growth rates of 4% and 6% respectively [18]. Financial Projections - Revenue projections for the company are as follows: - 2024: RMB 126,898 million - 2025: RMB 142,776 million - 2026: RMB 148,357 million - 2027: RMB 157,887 million - 2028: RMB 168,481 million - The expected growth rates for these years are 11.8%, 12.5%, 3.9%, 6.4%, and 6.7% respectively [4]. - Non-GAAP net profit is projected to be: - 2026: RMB 17,186 million - 2027: RMB 18,918 million - 2028: RMB 22,194 million - The growth rates for net profit are expected to be 72.5%, 16.5%, -16.8%, 10.1%, and 17.3% respectively [4]. User Metrics - The average monthly active users (MAU) for the main app are projected to be: - 2024: 710 million - 2025: 725 million - 2026: 732 million - 2027: 732 million - 2028: 732 million - The year-over-year growth rates for MAU are expected to decline from 5% in 2024 to 0% by 2027 [14]. Revenue Breakdown - The revenue breakdown for 2026 is projected as follows: - Advertising: RMB 86,700 million - Live streaming: RMB 36,225 million - Other services: RMB 25,432 million - E-commerce GMV: RMB 1,708,586 million [15]. - The report highlights that the advertising revenue is expected to grow at a slower pace due to market conditions, while AI applications are anticipated to drive growth in other segments [18].

公司评级 [Table_Invest] 买入-A/买入-H 当前价格 7.03 元/6.60 港元 合理价值 8.09 元/7.59 港元 前次评级 买入/买入 报告日期 2026-03-26 [Table_Page] 年报点评|农商行Ⅱ 证券研究报告 [Table_Title] 渝农商行(601077.SH)/重庆农村商 业银行(03618.HK) 主营向好，非息承压，对公零售质量分化 [Table_Summary] 核心观点： [联系人： Table_Contacts] 王宇 010-59136615 yfwangyu@gf.com.cn 972918116公共联系人2026-03-26 11:12:33 1 / 24 识别风险，发现价值 请务必阅读末页的免责声明 [Table_PicQuote] 相对市场表现 [分析师： Table_Author]倪军 -10% -2% 6% 14% 22% 30% 03/25 05/25 07/25 09/25 11/25 01/26 03/26 渝农商行 沪深300 | SAC 执证号：S0260518020004 | | --- | | 021-38003646 ...

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 24.10 and a fair value of HKD 29.65 [8][23]. Core Insights - The company achieved a net profit of RMB 244 million in 2025, exceeding expectations, with both major business lines performing well [9][10]. - The company’s revenue for 2025 was RMB 1.058 billion, representing a year-over-year growth of 35.1% [9][10]. - The gross margin improved slightly to 72.1%, benefiting from a higher proportion of high-margin product sales and operational efficiency [9][10]. - The company is expected to launch several new products, including a liquid embolic agent for treating vascular malformations, which is anticipated to be approved in 2026 [10][12]. Financial Forecasts - Revenue projections for 2026 to 2028 are as follows: - 2026: RMB 1.387 billion (31.1% growth) - 2027: RMB 1.808 billion (30.4% growth) - 2028: RMB 2.390 billion (32.2% growth) [3][18]. - Net profit forecasts for the same period are: - 2026: RMB 340 million - 2027: RMB 457 million - 2028: RMB 638 million [3][18]. - The company’s EBITDA is projected to grow significantly, reaching RMB 665 million by 2028 [3]. Business Segments - The neuro-interventional products segment generated RMB 676 million in sales in 2025, a 28% increase year-over-year, driven by new product penetration [9][10]. - The peripheral interventional products segment achieved sales of RMB 379 million, reflecting a 50.3% year-over-year growth, primarily due to rapid market acceptance of new products [9][10]. - The company is focusing on enhancing sales and operational efficiency, with R&D expenses decreasing as a percentage of revenue [10][11]. Market Position and Competitive Advantage - The company is positioned as a leader in the neurovascular and peripheral vascular intervention market, with a comprehensive product line developed over more than a decade [18][19]. - Participation in volume-based procurement has allowed the company to secure significant market share and improve sales volume [20][21]. - The company plans to leverage its partnership with OPTIMED to accelerate overseas market expansion [22].

Investment Rating - The report maintains a "Buy" rating for the company with a current price of 44.25 RMB and a fair value of 48.8 RMB [7]. Core Insights - The company achieved a revenue of 3.83 billion RMB in 2025, representing a year-on-year growth of 50.39%. However, the net profit attributable to shareholders decreased by 31.80% to 158 million RMB. Excluding foreign exchange losses and share-based payments, the adjusted net profit increased by 18.98% to 252 million RMB [7]. - The e-commerce sector saw significant growth, with advertising revenue from e-commerce clients reaching 1.14 billion RMB, up 122.8% year-on-year. The integrated marketing services revenue was 1.95 billion RMB, growing by 49.35% [7]. - The company has made advancements in AI marketing, launching the AI Drive 2.0 smart marketing solution and achieving a leading position in the programmatic advertising market in the Asia-Pacific region [7]. Financial Forecast - Revenue projections for the company are as follows: - 2024: 2.55 billion RMB (growth rate: 18.8%) - 2025: 3.83 billion RMB (growth rate: 50.4%) - 2026: 5.02 billion RMB (growth rate: 30.9%) - 2027: 6.40 billion RMB (growth rate: 27.7%) - 2028: 7.86 billion RMB (growth rate: 22.7%) [2][10]. - The forecasted net profit attributable to shareholders is: - 2024: 232 million RMB - 2025: 158 million RMB - 2026: 252 million RMB - 2027: 334 million RMB - 2028: 398 million RMB [2][10]. Segment Analysis - Integrated Marketing Services: - Revenue is expected to grow to 2.44 billion RMB in 2026, with a growth rate of 25% and a stable gross margin of 9% [8]. - Advertising Platform Business: - Revenue is projected to reach 2.57 billion RMB in 2026, with a growth rate of 40% and an expected gross margin of 20% [9]. Valuation Methodology - The report employs a segmented valuation approach, assigning a 1X PS multiple to integrated marketing services and an 8X PS multiple to advertising platform revenue, resulting in a total fair value of 230.3 billion RMB, equating to a fair value of 48.8 RMB per share [13].

Investment Rating - The report assigns a "Buy" rating to the company [2]. Core Insights - The company has established a unique AI-driven Pharma.AI platform that accelerates the drug development process, significantly reducing costs and time [7][21]. - The company has over 30 projects in its pipeline, with two advancing to Phase II clinical trials, indicating a diversified and innovative pipeline [7]. - The company is actively expanding collaborations with over 10 domestic and international pharmaceutical companies, which is expected to drive long-term growth [7]. - Revenue projections for 2025 and 2027 are estimated at $560 million and $2.12 billion, respectively, reflecting the company's unique business model and pipeline advancement [7]. Summary by Sections AI Development and Impact - AI has rapidly evolved since the early 1990s, significantly enhancing drug discovery efficiency [12][15]. - The application of AI in drug discovery can reduce time and costs by up to 50% compared to traditional methods [15]. Company Overview - The company was founded in 2014 and has built a world-class team for drug discovery and development, integrating advanced generative AI capabilities [21]. - The Pharma.AI platform is designed for end-to-end drug discovery and development, enhancing learning and performance through real-time feedback loops [21][26]. Pipeline and Clinical Development - The company has 12 pipelines that have received IND approval, with the fastest progressing to Phase II clinical trials in the U.S. and China [36]. - The TNIK inhibitor for idiopathic pulmonary fibrosis (IPF) has shown significant progress, with a rapid transition from target discovery to human clinical trials in just 18 months [36]. Financial Projections and Investment Recommendations - The company is expected to generate revenues of $56 million in 2025 and $212 million in 2027, driven by its innovative pipeline and business model [6][7]. - The report values the company at HKD 77.97 per share based on a 40x price-to-sales ratio for 2026 [7].

Investment Rating - The investment rating for the company is "Buy" with a current price of 27.27 CNY and a fair value of 30.89 CNY [4]. Core Insights - The company reported a revenue of 59.274 billion CNY for 2025, a slight decrease of 0.48% year-on-year, while the net profit attributable to shareholders was 5.105 billion CNY, an increase of 2.32% year-on-year. The cash dividend for the year totaled 5.024 billion CNY, with a per-share dividend of 1.45 CNY, continuing its high dividend commitment [4]. - The sales volume of meat products showed a positive trend throughout the year, with the average profit per ton remaining high at approximately 4,736 CNY, reflecting a year-on-year increase of 0.8%. The company expects further improvement in sales volume and profit margins in 2026 due to enhanced sales strategies and new channel developments [4]. - The slaughtering business generated 26.32 billion CNY in revenue, down 2.3% year-on-year, with a significant increase in volume by 15.9% but a decrease in price by 15.4%. The company aims to expand market share through a strategy of increasing volume while stabilizing profits [4]. - The breeding business saw a significant reduction in losses, with revenue of 9.61 billion CNY, up 20.2% year-on-year, and losses narrowed to 80 million CNY from 370 million CNY in 2024, attributed to improved breeding technology and capacity utilization [4]. - Profit forecasts for 2026-2028 indicate net profits of 5.352 billion CNY, 5.535 billion CNY, and 5.702 billion CNY, representing year-on-year growth rates of 4.8%, 3.4%, and 3.0% respectively. The company is valued at a PE ratio of 20 times for 2026, leading to a fair value estimate of 30.89 CNY per share [4]. Financial Summary - Revenue projections for 2024A, 2025A, 2026E, 2027E, and 2028E are 59.715 billion CNY, 59.460 billion CNY, 61.336 billion CNY, 63.369 billion CNY, and 65.344 billion CNY respectively, with growth rates of -0.6%, -0.4%, 3.2%, 3.3%, and 3.1% [3][7]. - The EBITDA for the same years is projected at 8.726 billion CNY, 8.688 billion CNY, 8.450 billion CNY, 8.646 billion CNY, and 8.875 billion CNY [3]. - The net profit attributable to shareholders is expected to be 4.989 billion CNY, 5.105 billion CNY, 5.352 billion CNY, 5.535 billion CNY, and 5.702 billion CNY, with corresponding growth rates of -1.3%, 2.3%, 4.8%, 3.4%, and 3.0% [3][7]. - The earnings per share (EPS) are projected to be 1.44 CNY, 1.47 CNY, 1.54 CNY, 1.60 CNY, and 1.65 CNY for the years 2024A to 2028E [3][7].

1. Report Industry Investment Rating No relevant content provided. 2. Core Views of the Report - The current real - estate bond market shows three characteristics: valuation has stopped falling, risks are clear, and spreads are differentiated. The impact of the Vanke event is significantly differentiated, with a greater impact on state - owned enterprises and limited impact on mixed - ownership and private enterprises [3]. - Assuming that the real - estate bond spreads are repaired to the lowest point of the year and the 10 - year Treasury bond yield drops by 10BP, extending the duration to bet on the repair of high - quality central and local state - owned enterprises can obtain excess returns. The actual repair process may be slow, and coupon income is the most certain source of return. It is recommended to adopt a strategy combining "bottom - position allocation + band trading" [3]. 3. Summary According to the Directory 3.1 Vanke Event Process and Its Impact on Real - Estate Bonds 3.1.1 Vanke Debt Extension Event Process In late November 2025, Vanke initiated debt extension negotiations for multiple domestic bonds due to large - scale debt maturities and liquidity tensions. After several setbacks, some bonds were successfully extended in January 2026 [8]. 3.1.2 Differentiated Impact of Vanke's Debt Extension Event - **Mixed - ownership and private enterprises**: The impact on private real - estate enterprises' bonds was relatively limited. The market had already been highly sensitive to their credit risks, and the Vanke event was generally regarded as a company - specific problem rather than a recurrence of systemic risks for private enterprises [13]. - **State - owned enterprises**: The negotiation of debt extension by Vanke had a significant impact on the bond prices of state - owned real - estate enterprises. It made investors re - evaluate the debt risks of state - owned real - estate enterprises [14]. 3.2 Current Right - hand Position and Return Space of Real - Estate Bonds 3.2.1 Review of the Default Process of Real - Estate Bonds since 2015 The credit risk evolution of the real - estate industry since 2015 has gone through five stages: the policy - easing period from 2015 - 2017 with only individual small and medium - sized real - estate enterprises facing operational risks; the first wave of defaults by small and medium - sized real - estate enterprises from 2018 - 2019 due to tightened financing; the spread of risks to large real - estate enterprises with high - leverage expansion from 2020 - the first half of 2021 under the "Three Red Lines" policy; the systemic credit crisis of leading real - estate enterprises from the second half of 2021 to 2024 due to a sharp decline in sales and stricter pre - sale fund supervision; and the approaching end of the real - estate default wave in 2025 [22]. 3.2.2 Characteristics of the Current Stage of Real - Estate Bonds - **Valuation has stopped falling**: The valuation of mixed - ownership and private enterprises has recovered first, and the spreads of state - owned enterprises have stopped hitting new highs. The panic selling caused by the Vanke event has been basically digested [27]. - **Risks are clear**: The Vanke debt extension event has a clear disposal path. A 40% immediate recovery rate has broken the pessimistic expectation of "losing all principal", and the arrangement of extending the remaining 60% of the debt for one year provides a reference for subsequent debt disposal [31]. - **Spreads are differentiated**: The market is now distinguishing between good and bad, and pricing is returning to individual credit qualifications. Some financially sound entities have seen their spreads recover first, while those with weaker financial performance or higher leverage pressure are still trading at high levels [33]. 3.2.3 Yield Calculation under the Repair Assumption - **Calculation assumptions**: A unified holding period of one year, all bonds are fully held. The 10 - year Treasury bond is used as the benchmark, and it is assumed that its yield will drop to the lowest point in the past year. For credit bonds, it is assumed that the yields of each variety will drop to the lowest point in the past year [41]. - **Calculation results**: The comprehensive yield of 2 - 3 - year high - grade state - owned real - estate bonds is in the range of 2.8% - 6.4%; the yield of 1 - year high - grade state - owned real - estate bonds is in the range of 1.8% - 2.4%; the comprehensive yield of the 10 - year Treasury bond is 2.94%; the yield of 1 - year mixed - ownership and private real - estate bonds is in the range of 2.3% - 2.9%. Extending the duration to bet on the spread repair of high - quality central state - owned enterprises can obtain higher excess returns [42][44][45][46]. 3.3 Coupon Strategy: Allocation Value of High - Quality Real - Estate Bond Entities 3.3.1 Central State - Owned Real - Estate Enterprises Due to the risk - aversion sentiment caused by the Vanke event, some high - quality central state - owned real - estate bonds have experienced irrational valuation corrections, but their long - term default risks are low. It is recommended to focus on leading entities with good financial performance, strong shareholder strength, and core - city layouts, such as Poly Developments and Holdings Group Co., Ltd., China Resources Land Limited, and China Green Development Group Co., Ltd. The duration can be moderately extended from less than one year to 1 - 3 years [50]. 3.3.2 Local State - Owned Real - Estate Enterprises The overall debt risks of local state - owned real - estate entities with large outstanding bond volumes are controllable. It is recommended to focus on entities in regions with good economic development, strong shareholder backgrounds, and good financial performance, such as Shanghai Lujiazui Group Co., Ltd., Guangzhou Urban Construction Development Co., Ltd., and Beijing Urban Construction Investment & Development Co., Ltd. [53]. 3.3.3 Mixed - Ownership and Private Real - Estate Enterprises Mixed - ownership and private real - estate enterprises are not the focus of allocation. Only institutions with high - risk tolerance can moderately bet on short - term investment opportunities for bonds with a maturity of less than one year. It is advisable to choose entities with a high willingness of shareholder support and sound financial conditions [57][59].

Investment Rating - The investment rating for the company is "Buy" with a current price of HKD 14.22 and a fair value of HKD 19.86 [5]. Core Insights - The main brand's operations are stabilizing, while the sub-brands and takeout services are experiencing rapid growth [3]. - The company reported a revenue of RMB 432.3 billion for the full year 2025, reflecting a year-on-year growth of 1.1%, while the net profit attributable to shareholders was RMB 40.5 billion, down 14.0% year-on-year [10]. - The average customer spending and table turnover rates for the main brand have stabilized, with a table turnover rate of 3.9 times and an average customer spending of RMB 97.7 in 2025 [10]. - The company is cautiously expanding its main brand while focusing on the growth of sub-brands, with a net decrease of 51 direct stores in 2025 [10]. - The company maintains a high dividend level, proposing a total dividend of approximately RMB 35 billion, which accounts for 86% of the net profit attributable to shareholders [10]. - The profit forecast for 2026-2028 estimates net profits of RMB 44 billion, RMB 48 billion, and RMB 51 billion respectively, with a target price based on a 22x PE ratio for 2026 [10]. Financial Summary - Revenue projections (in RMB million) for 2024A to 2028E are as follows: 42,755 (2024A), 43,225 (2025A), 47,565 (2026E), 50,498 (2027E), and 53,368 (2028E) with growth rates of 3.1%, 1.1%, 10.0%, 6.2%, and 5.7% respectively [4]. - EBITDA is projected to be 9,074 (2024A), 5,779 (2025A), 8,772 (2026E), 9,128 (2027E), and 9,554 (2028E) [4]. - The net profit attributable to shareholders is expected to be 4,708 (2024A), 4,050 (2025A), 4,429 (2026E), 4,768 (2027E), and 5,122 (2028E) [4]. - The company’s return on equity (ROE) is projected to be 45.1% (2024A), 40.4% (2025A), 42.2% (2026E), 43.2% (2027E), and 44.4% (2028E) [4].

Group 1: Oil Price Threshold Effects - The relationship between oil prices and major asset prices is not linear and exhibits threshold effects, where crossing certain oil price levels leads to different asset price responses[4] - Three transmission mechanisms for the threshold effect of oil prices are identified: investor psychological anchors, central bank tolerance levels, and corporate breakeven points[5] - Historical data shows that 60% of oil prices are below $75/barrel and 80% are below $100/barrel, establishing these as key thresholds for asset pricing[8] Group 2: Impact on Inflation and CPI - A simple OLS regression indicates that a 10% increase in Brent crude oil prices could raise the U.S. CPI energy component by approximately 2.7%, with potential increases of 5.4% and 8.1% for 20% and 30% increases, respectively[6] - During the 2022 Russia-Ukraine conflict, Brent crude prices rose by an average of 43%, leading to an 11.6% increase in the U.S. CPI energy component[6] Group 3: Asset Performance Under Different Oil Price Scenarios - In the "medium oil price range" ($75-$100/barrel), the Nasdaq index shows the best performance with an average increase of 2.61% in the following months[10] - The 10-year U.S. Treasury yield increases by an average of 42.6 basis points when oil prices exceed $100/barrel, compared to 8.2 basis points in the medium oil price range[10] - The VIX index rises by an average of 13.5% in the "high oil price range," indicating increased market volatility[11] Group 4: Sensitivity of Assets to Oil Price Changes - The sensitivity of major U.S. stock indices to oil price changes turns negative once oil prices exceed $100/barrel, indicating a shift from demand-driven to cost-push inflation dynamics[22] - The 10-year U.S. Treasury yield shows a significant increase in sensitivity to oil price changes in high oil price scenarios, with coefficients rising from -0.169 to 1.601 when oil prices exceed $100/barrel[23] - Gold prices exhibit a U-shaped relationship with oil prices, performing best in high oil price scenarios and worst in medium oil price scenarios[16]